Skip to the page content
Your donations
Passes our checks

Translational Genomics Research Institute

EIN 75-3065445 · Phoenix, AZ

Public records show a registered, tax-exempt organization in good standing.

LegitimacyPassesRegistration and standingFinancial healthFair54 out of 100GovernanceStrong100 out of 100Impact evidenceDescribes programsHow well its results are evidenced

What it says it does

PLEASE SEE SCHEDULE O

Income
$75.9 million
Spending
$86.3 million
Spent on programs
71%
Reserves
4.5 months of spending
Largest source of income
fees for its services, 46%
Employees
406
Volunteers
70
Highest pay
$7.1 million, bd & vice chrm/coh ceo & pres.

Source: Form 990 for the year ending September 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Fair: 54 out of 100. Higher than 28% of charities in its peer group (medical research, $10m to $100m).

  • Reserves

    20 of 35

    Spendable reserves would cover 4.5 months of spending.

  • Debt

    10 of 20

    It owes 37% of what it owns.

  • Living within its means

    4 of 15

    Spending exceeded income by 14% of income.

  • Income trend

    5 of 15

    Income fell 12% on the year before.

  • Spending floor

    15 of 15

    71% of spending went to programs and raising each dollar of donations cost 0 cents.

Source: Form 990 for the year ending September 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Strong: 100 out of 100. Higher than 45% of charities in its peer group (medical research, $10m to $100m).

  • Independent board

    25 of 25

    10 of 12 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    8 of 8

    Has a written whistleblower policy.

  • Record keeping policy

    7 of 7

    Has a written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    10 of 10

    Gave the board a copy of this return before filing it.

  • Pay set independently

    5 of 5

    Sets its chief executive's pay through independent review and comparison.

  • Independent check of accounts

    15 of 15

    Its accounts were audited by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending September 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (6)
  1. $16.9 million spent. CLINICAL GENOMICS AND THERAPEUTICS TGEN'S CLINICAL GENOMICS AND THERAPEUTICS DIVISION SEEKS TO ADVANCE THE UNDERSTANDING OF CLINICALLY RELEVANT GENOMIC AND OTHER -OMIC CHANGES RELATED TO CANCER AND LEVERAGE SUCH INSIGHTS TO IMPROVE HEALTH OUTCOMES THROUGH MORE ACCURATE AND EFFECTIVE DIAGNOSIS, TREATMENT, AND MONITORING. WITH THE IMPLEMENTATION OF INCREASINGLY SOPHISTICATED MOLECULAR TECHNOLOGIES, EMPHASIS IS PLACED ON TRAINING THE NEXT GENERATION OF BOTH RESEARCHERS AND CLINICIANS CAPABLE OF DRIVING THIS MISSION FORWARD.
  2. $10.4 million spent. EARLY DETECTION AND PREVENTION DISEASES ARE MOST EASILY PREVENTED, OR TREATED EFFECTIVELY, IF THEY ARE DETECTED EARLY. TGEN'S EARLY DETECTION AND PREVENTION DIVISION IS DEDICATED TO IDENTIFYING DISEASES AT THEIR EARLIEST STAGES BY LEVERAGING ADVANCED -OMIC TECHNOLOGIES, SURPASSING THE CAPABILITIES OF TRADITIONAL METHODS. BY TRANSFORMING THESE DISCOVERIES INTO INNOVATIVE DIAGNOSTIC AND THERAPEUTIC SOLUTIONS, WE STRIVE TO STOP DISEASES BEFORE THEY START, ENHANCE PATIENT OUTCOMES, AND SAVE LIVES
  3. $6.2 million spent. BIOINNOVATION AND GENOME SCIENCES TGEN'S DIVISION OF BIOINNOVATION AND GENOME SCIENCES IS DEDICATED TO UNDERSTANDING THE GENETIC AND MOLECULAR MECHANISMS UNDERLYING HEALTH AND DISEASE THROUGH THE APPLICATION AND ADVANCEMENT OF CUTTING-EDGE GENOMICS TECHNOLOGIES. WE SUPPORT KEY RESOURCES, TECHNOLOGY DEVELOPMENT, EXPERIMENTAL INNOVATION, AND COMPUTATIONAL APPROACHES TO ADDRESS LEADING-EDGE QUESTIONS IN BIOLOGY AND MEDICINE WITH THE GOAL OF IMPROVING PATIENT LIVES.
  4. $27.4 million spent. PLEASE SEE SCHEDULE O
  5. OTHER SCIENCE, BY NATURE, IS AN ITERATIVE PROCESS: A QUESTION AND ANSWER CYCLE OF REFINEMENT AND FURTHER EXPERIMENTATION IN SEARCH OF MEDICAL ADVANCES, WHETHER A NEW DIAGNOSTIC TEST OR TREATMENT. IN THIS REGARD, TGEN HAS HELPED BRIDGE THE GAP BETWEEN LABORATORY DISCOVERIES AND PRACTICAL APPLICATIONS IN PATIENT CARE. OUR APPROACH HAS LED TO SIGNIFICANT STRIDES IN UNDERSTANDING DISEASES AT THE MOLECULAR LEVEL, PAVING THE WAY FOR MORE PRECISE DIAGNOSTIC TOOLS AND GROUNDBREAKING TREATMENTS. TODAY, OUR CAPACITY TO UNDERSTAND AND LEVERAGE INFORMATION FROM THE HUMAN GENOME HAS NEVER BEEN GREATER. TGEN'S ABILITY TO BRING EMERGING NEW METHODS FOR INTERROGATING A PATIENT'S GENOME INTO THE CLINICAL CARE OF PATIENTS, THE REVOLUTION IN FASTER AND LOWER-COST WAYS OF CANCER DETECTION AND THE PATHS THAT REACH THE URBAN, THE RURAL AND MORE DIVERSE POPULATIONS, HAS NEVER BEEN GREATER. THE SEQUENCE COST PER-PATIENT OVER THE PAST DECADE HAS DROPPED DRAMATICALLY. THIS MEANS TGEN CAN SEQUENCE MORE PATIENTS, OR SEQUENCE A PATIENT AGAIN, TO UNDERSTAND HOW THEIR DISEASE IS PROGRESSING. AS PART OF A NATIONAL HEALTH SYSTEM, THIS HELPS DRIVE RESEARCH DISCOVERY, NEW METHODS FOR EARLY DETECTION, AND MORE CLINICAL TRIALS. SEQUENCING ACCURACY HAS ALSO IMPROVED DRAMATICALLY. THIS INCREASED ACCURACY MEANS TGEN CAN DETECT CANCER EARLIER - PERHAPS IN ITS INFANCY - WHICH LEADS TO IMPROVED SCREENING, POST-TREATMENT MONITORING AND BIOPSIES WITH A LOW PERCENTAGE OF TUMOR PRESENT. THIS ALSO ALLOWS US TO EXPAND GENOMIC TESTING INTO MORE CANCER TYPES.
  6. (EXPENSES $ 27,384,445 INCLUDING GRANTS OF $ 0)(REVENUE $ 26,417,426) PLEASE SEE SCHEDULE O

Source: Form 990 for the year ending September 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.

  3. Are donations tax-deductible? Passed.

    On the IRS list of organizations eligible to receive tax-deductible contributions.

    Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending September 2025.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since December 2002.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.